Form 6-K Acasti Pharma Inc. For: Jan 02
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
For the month of: January 2018 | Commission File Number: 001-35776 |
ACASTI PHARMA INC.
(Name of Registrant)
545 Promende du Centropolis
Suite 100
Laval, Québec
Canada H7T 0A3
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A
This Report on Form 6-K including the exhibits hereto shall be deemed to be incorporated by reference into Acasti Pharma Inc.’s registration statement on Form S-8 (File No. 333-191383) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ACASTI PHARMA INC. | ||
Date: January 2, 2018 | By: | a/s/ Jan D’Alvise |
Name: Jan D’Alvise Title: Chief Executive Officer |
EXHIBIT INDEX
Exhibit | Description of Exhibit |
99.1 | Press release dated Janury 2, 2018 |
Exhibit 99.1
Acasti Pharma To Present at Biotech Showcase Conference
Laval, Québec, CANADA – January 2, 2018 – Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that Jan D’Alvise, the company’s president and chief executive officer will present at Biotech Showcase Conference on Wednesday, January 10 at 11:00 a.m. PT in Yosemite - A of the Ballroom Level. The conference will take place at the Hilton San Francisco Union Square.
A live audio webcast of the presentation will be available under the “News & Investors” section of Acasti's website at www.acastipharma.com. A replay of the presentation will be available for 60 days following the event.
About Acasti Pharma
Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company’s strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. For more information, visit www.acastipharma.com.
# # #
Acasti Contact:
Jan D’Alvise
Chief Executive Officer
450-686-4555
www.acastipharma.com
Media Contact:
Jessica Dyas
Canale Communications
619-849-5385
Investor Relations Contact:
Glen Akselrod
Bristol Capital Ltd.
(905) 326-1888 ext 10
Page 1 of 1
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neptune Wellness Solutions' (NEPT) Sprout Foods Receives Notice of Default
- Orexo publishes the Annual and Sustainability Report for 2023
- 0xGPU Presents New Features Enhancing GPU&NPU Decentralized Computing
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!